Can-Fite Completes 50% Patient Enrollment in Phase III Rheumatoid Arthritis Study & Implements Interim Analysis
Stock Information for Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Loading
Please wait while we load your information from QuoteMedia.